Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Phase 3 PEAK results in 2^nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December

Breakthrough Therapy Designation granted for bezuclastinib; New Drug Application (NDA) filing for NonAdvSM remains on track for year-end 2025 

Read more at globenewswire.com